Barclays sets USD 345.00 target for Ligand Pharmaceuticals stock

Published on 10/15/2026 at 21:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ligand reports results October 29, 2026. Ligand Pharmaceuticals stock costs EUR 267.00 on October 15, 2026, up 1.65 percent on Nasdaq.

Analyst view and calendar

Barclays initiated coverage with a USD 345.00 target on September 25, 2026.
Ligand Pharmaceuticals will report third-quarter results on October 29, 2026.
Ligand Pharmaceuticals stock costs EUR 267.00 at 9:38 p.m. CEST at Lang & Schwarz on October 15, 2026, up 1.65 percent on Nasdaq.
Ligand Pharmaceuticals has a price earnings ratio of 32.00 and a USD 6.0 billion market capitalization.

LGND, US53220K5048, Illustration mit AI erstellt.

Barclays initiated coverage of Ligand Pharmaceuticals on September 25, 2026, with an Overweight rating and a USD 345.00 price target, according to Investing.com. Against the Nasdaq price of USD 299.87 on October 15, 2026, the target is 15.05 percent higher. Ligand Pharmaceuticals stock was trading at EUR 267.00 at Lang & Schwarz on October 15, 2026 at 9:38 p.m. CEST, up 1.65 percent on Nasdaq.

Results date October 29, 2026

Ligand Pharmaceuticals will report third-quarter 2026 results on October 29, 2026, with its conference call scheduled for 8:30 a.m. Eastern time. Markets Insider carried the company announcement dated October 15, 2026.

Stock stays below its yearly high

The Nasdaq share price of USD 299.87 stood 8.19 percent below the 52-week high of USD 326.63 and 70.49 percent above the low of USD 175.89 on October 15, 2026. The session volume was 241,474 shares against an average of 250,210 shares. The earlier second-quarter report showed revenue of USD 63.69 million, up 33.80 percent year over year, while adjusted earnings per share reached USD 2.37 against a USD 1.97 consensus estimate, according to MarketBeat.

Valuation and royalty model

Ligand Pharmaceuticals had a market capitalization of USD 6.0 billion and a price earnings ratio of 32.00 on October 15, 2026. The company describes itself as a royalty aggregator with economic interests in more than 200 development and commercial-stage assets. That model makes the October 29 results important for tracking royalty revenue and partner activity rather than only product sales.

Comparison with peers

Ligand Pharmaceuticals: plus 1.65 percent, P/E 32.00, market capitalization USD 6.0 billion
Royalty Pharma plc (Nasdaq, USD): plus 1.39 percent, P/E 34.39, market capitalization USD 26.6 billion
Amgen Inc. (Nasdaq, USD): plus 2.64 percent, P/E 27.22, market capitalization USD 236.5 billion

Euro quote after hours

The euro quotation puts Ligand Pharmaceuticals below its Nasdaq share value after currency conversion, while the target comparison remains based on the home-exchange price in USD. The next scheduled company date is October 29, 2026.

The further course of trading is shown by the continuously updated real-time quote of Ligand Pharmaceuticals stock.